Lu Yu

No. 11 Xizhimen South Street
Xizhimen, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.

Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.

Journal: Cancer
Published: August 26, 2025

KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.

KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.

Journal: Cancers
Published: June 04, 2025

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Journal: Haematologica
Published: May 15, 2025

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.

Journal: Haematologica
Published: December 04, 2024

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.

Journal: Cancer
Published: May 07, 2024

Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.

Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.

Journal: Blood science (Baltimore, Md.)
Published: January 01, 2024

Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.

Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.

Journal: Journal of cancer research and clinical oncology
Published: March 25, 2021

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Journal: Medicine
Published: November 27, 2019

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.

Journal: Scientific reports
Published: August 05, 2019

Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.

Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.

Journal: British journal of haematology
Published: March 11, 2018

Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.

Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.

Journal: Journal of cancer research and clinical oncology
Published: January 05, 2018

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.

Journal: BMC cancer
Published: August 28, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026